期刊文献+

肺癌合并抗利尿激素分泌不当综合症6例临床分析 被引量:5

Syndrome of inappropriate anti-diuretic hormone in lung-cancer patients: six cases
下载PDF
导出
摘要 目的:研究肺癌合并抗利尿激素分泌不当综合症(syndrome of inappropriate antidiuretic hormone secretion,SIADH)引起的低钠血症的临床特点、治疗方法及对评价预后的价值。方法:回顾分析大庆油田总医院2010年6月至2013年12月收治6例肺癌合并SIADH的临床资料,其中小细胞肺癌4例、腺癌1例、鳞癌1例。结果:对于不同血钠水平的患者给予不同的治疗方案,患者的乏力、神经系统等症状及血钠、尿钠、血浆渗透压均得到改善。结论:部分肺癌患者出现SIADH引起的低钠血症,出现电解质紊乱提示预后差、死亡率高,并因临床重视不够而出现延误治疗的情况。对于确诊的患者给予适当的治疗后,不论是临床症状还是血钠水平均可获得明显改善。 Objective:To investigate the clinical characteristics, treatment, and evaluation of the prognosis of syndrome of inap-propriate anti-diuretic hormone (SIADH) in lung-cancer patients. Methods:We review the clinical data of six lung cancer cases, includ-ing four small cell lung cancer, one adenocarcinoma, and one squamous cell carcinoma, with SIADH complication. All six cases were treated in our hospital over the past three years. Results:Patients with various serum sodium levels were provided different therapeutic regimens. Symptoms of fatigue and nervous system disorders, plasma sodium, urine sodium, and plasma osmotic pressure were alleviat-ed. Conclusion:SIADH is a common complication of lung cancer, particularly in small lung cancer cases. Electrolyte disturbances indi-cate poor prognosis, high mortality rate, and delay in treatment because of clinical interest. After a final diagnosis has been made and ap-propriate treatment has been administered, clinical symptoms were relieved and blood sodium levels were quickly and significantly im-proved in these patients.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2014年第4期259-261,共3页 Chinese Journal of Clinical Oncology
关键词 肺癌 抗利尿激素分泌不当综合症 低钠血症 lung neoplasms inappropriate ADH syndrome hyponatremia
  • 相关文献

参考文献12

  • 1Onitilo AA, Kio E, Doi SA. Tumor-related hyponatremia[J]. Clin Med Res, 2007, 5(4):228-237.
  • 2Schrier RW.Vasopressin and aquaporin 2 inclinical disorders of wa-ter homeostasis[J]. Semin Nephrol, 2008, 28(3):289-296.
  • 3Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research[J]. BrJ Cancer, 1990, 61 (4):597-604.
  • 4Castillo JJ, Vincent M, Justice E. Diagnosis and management of hy- ponatremia in cancer patients[J]. Oncologist, 2012, 17(6):756-765.
  • 5Ghali JK, Farah JO, Daifallah S, et al. Conivaptan and its role in the treatment of hyponatremia [J]. Drug Des Devel Ther, 2009,29 (3) :253-268.
  • 6Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopres- sin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excre- tion in human heart failure[J]. Am J Physiol Renal Physiol, 2006, 290(2) :F273-F278.
  • 7VerbalisJG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion[J]. Eur J Endocrlnol, 2011, 164(5): 725-732.
  • 8Berl T, O uittnat-PeUetier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia[J]. J Am Soc Nephrol, 2010, 21(4):705-712.
  • 9Petereit C, Zaba O, Teber I, et al. A rapid and efficient way to man- age hyponatremia in patients with SIADH and small cell lung can- cer: treatment with tolvaptan[J]. BMC Pulm Med, 2013, 29(13):55.
  • 10Artom N, Oddo S, Pende A, et al. Syndrome of inappropriate antidi- uretic hormone secretion and Ibuprofen, a rare association to be considered: role of tolvaptan[J]. Case Rep Endocrinol, 2013, 2013: 818259.

同被引文献29

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部